# A Mutiple-dose Study of IBI3033 in Healthy Participants

> **NCT07456839** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 8 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Placebo
- **DRUG:** IBI3033

## Key facts

- **NCT ID:** NCT07456839
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-11-13
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07456839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07456839, "A Mutiple-dose Study of IBI3033 in Healthy Participants". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT07456839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*